-
Kenya's economy faces climate change risks: World Bank
-
More Nepalis drive electric, evading global fuel shocks
-
Latecomer Japan eyes slice of rising global defence spending
-
German fertiliser makers and farmers struggle with Iran war fallout
-
OPEC+ to make first post-UAE production decision
-
Massive crowds fill Rio's Copacabana beach for Shakira concert
-
US airlines step up as Spirit winds down
-
Aviation companies step up as Spirit winds down
-
'Bookless bookstore': audio-only book shop opens in New York
-
Venezuelan protesters call government wage hike a joke
-
S&P 500, Nasdaq end at fresh records on tech earnings strength
-
Pope names former undocumented migrant as US bishop of West Virginia
-
Trump says will raise US tariffs on EU cars to 25%
-
ExxonMobil CEO sees chance of higher oil prices as earnings dip
-
After Madonna and Lady Gaga, Shakira set for Rio beach mega-gig
-
King Charles gets warm welcome in Bermuda after whirlwind US visit
-
Coe hails IOC gender testing decision
-
Baguettes take centre stage on France's Labour Day
-
Iran offers new proposal amid stalled US peace talks
-
French hub monitors Hormuz tensions from afar
-
Oil steady after wild swing, stocks diverge in thin trading
-
Chinese swimmer Sun Yang reports cyberbullying to police
-
Iran activates air defences as Trump faces congressional deadline
-
India's cows offer biogas alternative to Mideast energy crunch
-
Crude edges up after wild swing, stocks track Wall St rally
-
Formerra Appoints Matt Borowiec as Chief Commercial Officer
-
New Princess Diana documentary promises her own words
-
Oil slumps after hitting peak, US indices reach new records
-
Venezuela leader hikes minimum wage package by 26%
-
Apple earnings beat forecasts on iPhone 17 demand
-
Bangladesh signs biggest-ever plane deal for 14 Boeings
-
Musk grilled on AI profits at OpenAI trial
-
Venezuela opens arms to world with Miami-Caracas flight
-
US Congress votes to end record government shutdown
-
First direct US-Venezuela flight in years arrives in Caracas
-
Just telling nations to quit fossil fuels 'not realistic': COP31 chief
-
Trump hails 'greatest king' Charles as state visit wraps up
-
Drivers help study road-trip mystery: what became of bug splats?
-
Oil strikes 4-year peak, stocks rise
-
Iran's supreme leader defies US blockade as oil prices soar
-
White House against Anthropic expanding Mythos model access: report
-
Oil crisis fuels calls to speed up clean energy transition
-
European rocket blasts off with Amazon internet satellites
-
Nigerian airlines avert shutdown as Mideast war hikes fuel prices
-
ArcelorMittal boosts sales but profits squeezed
-
German growth beats forecast but energy shock looms
-
Air France-KLM trims 2026 outlook over Middle East war impact
-
Oil surges 7% to top $126 on Trump blockade warning
-
Volkswagen warns of more cost cuts as profits plunge
-
Rolls-Royce confident on profits despite Mideast war disruption
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
J.Bondarev--CPN